Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.91)
# 218
Out of 4,520 analysts
80
Total ratings
71.1%
Success rate
61.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Maintained: Buy | $22 | $10.73 | +105.03% | 6 | Jun 29, 2026 | |
| CGON CG Oncology | Maintained: Buy | $82 | $71.85 | +14.13% | 8 | Jun 23, 2026 | |
| LONA LeonaBio | Initiated Coverage: Buy | $20 | $7.22 | +177.01% | 1 | May 27, 2026 | |
| TARA Protara Therapeutics | Maintained: Buy | $24 | $4.10 | +485.37% | 7 | May 20, 2026 | |
| TNGX Tango Therapeutics | Downgraded: Hold | $14 → $24 | $28.56 | -15.97% | 4 | May 15, 2026 | |
| RLMD Relmada Therapeutics | Maintained: Buy | $12 | $5.24 | +129.01% | 2 | May 13, 2026 | |
| ERAS Erasca | Maintained: Buy | $18 | $19.17 | -6.10% | 5 | May 12, 2026 | |
| JANX Janux Therapeutics | Maintained: Buy | $30 → $26 | $16.26 | +59.90% | 7 | May 8, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $120 → $172 | $186.16 | -7.61% | 8 | May 7, 2026 | |
| SMMT Summit Therapeutics | Maintained: Hold | $17 → $16 | $13.81 | +15.86% | 4 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $40.23 | -0.57% | 8 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $11.47 | +248.74% | 3 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.82 | - | 1 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $1.79 | +346.93% | 4 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 | $27.76 | +29.68% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.25 | n/a | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.87 | n/a | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.00 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.49 | n/a | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $22.26 | n/a | 1 | Oct 31, 2022 |
ORIC Pharmaceuticals
Jun 29, 2026
Maintained: Buy
Price Target: $22
Current: $10.73
Upside: +105.03%
CG Oncology
Jun 23, 2026
Maintained: Buy
Price Target: $82
Current: $71.85
Upside: +14.13%
LeonaBio
May 27, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.22
Upside: +177.01%
Protara Therapeutics
May 20, 2026
Maintained: Buy
Price Target: $24
Current: $4.10
Upside: +485.37%
Tango Therapeutics
May 15, 2026
Downgraded: Hold
Price Target: $14 → $24
Current: $28.56
Upside: -15.97%
Relmada Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $12
Current: $5.24
Upside: +129.01%
Erasca
May 12, 2026
Maintained: Buy
Price Target: $18
Current: $19.17
Upside: -6.10%
Janux Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $30 → $26
Current: $16.26
Upside: +59.90%
Revolution Medicines
May 7, 2026
Maintained: Buy
Price Target: $120 → $172
Current: $186.16
Upside: -7.61%
Summit Therapeutics
May 1, 2026
Maintained: Hold
Price Target: $17 → $16
Current: $13.81
Upside: +15.86%
Apr 20, 2026
Maintained: Buy
Price Target: $40
Current: $40.23
Upside: -0.57%
Apr 20, 2026
Maintained: Buy
Price Target: $40
Current: $11.47
Upside: +248.74%
Mar 26, 2026
Maintained: Buy
Price Target: n/a
Current: $1.82
Upside: -
Mar 17, 2026
Maintained: Buy
Price Target: $8
Current: $1.79
Upside: +346.93%
Dec 8, 2025
Maintained: Buy
Price Target: $36
Current: $27.76
Upside: +29.68%
May 15, 2025
Reiterated: Buy
Price Target: $5
Current: $2.25
Upside: n/a
May 7, 2025
Reiterated: Buy
Price Target: $8
Current: $2.87
Upside: n/a
Apr 1, 2025
Maintained: Hold
Price Target: n/a
Current: $5.00
Upside: n/a
Jul 30, 2024
Downgraded: Hold
Price Target: n/a
Current: $4.49
Upside: n/a
Oct 31, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $22.26
Upside: n/a